Storia in 3 fonti

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Merck & Co (NYS

Merck's Phase 3 KEYNOTE-C93 trial showed Keytruda improved progression-free survival over chemotherapy in advanced endometrial cancer.

Raccontata da

morningstar.com

benzinga.com

fiercepharma.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Merck & Co (NYS

Merck's Phase 3 KEYNOTE-C93 trial showed Keytruda improved progression-free survival over chemotherapy in advanced endometrial cancer.

originale

morningstar.com1 mese fa

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain…

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to…

Leggi questa versione →

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Merck & Co (NYS

Confronto fonti

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Merck & Co (NYS

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain…

Timeline cronologica

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or…

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Merck & Co (NYS

Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first

Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first